Navigation Links
ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
Date:4/8/2008

LEUVEN, Belgium, April 9 /PRNewswire-FirstCall/ -- ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on vascular diseases, eye diseases and cancer, announces today that it has completed patient enrolment for its Phase II MITI IV study. The primary purpose of this study is to evaluate the safety and preliminary efficacy of microplasmin when administered intravenously to acute stroke patients between four and twelve hours after the onset of the stroke.

MITI IV (Microplasmin in Treatment of Ischemic stroke - IntraVenous) is a Phase II, multicentre, double-blinded, placebo-controlled, ascending-dose clinical trial evaluating the safety of the intravenous administration of microplasmin in 40 patients with acute ischemic stroke. The trial is investigating three dose regimens of microplasmin (2, 3, and 4 mg/kg total dose) and placebo. The trial is also designed to provide preliminary efficacy data using radiographic assessments and plasma surrogate biomarkers. Clinical outcomes are assessed at seven days and 30 days post-treatment, and at each of these visits neurological assessments are performed.

Microplasmin is a truncated form of the natural human protein plasmin, which plays a key role in dissolving blood clots such as those that cause acute stroke. It is a direct-acting thrombolytic agent that has the potential to restore blood flow efficiently within an extended period after a stroke event and has potentially fewer side-effects than other thrombolytic agents. Currently the only approved pharmacologic treatment of acute ischemic stroke is tPA, an indirect-acting thrombolytic. However tPA must be administered within three hours after the stroke has occurred and has the risk of causing unwanted bleeding events.

Dr. Steve Pakola, Chief Medical Officer of ThromboGenics, commenting on today's announcement said: "I am very pleased that we have completed enrolment in this study. We look forward to the results, which shoul
'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ThromboGenics Announces 2007 Full Year Results
2. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
3. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
4. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
5. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
6. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
7. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
8. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
9. Compressus Completes Interoperability Implementation for E-Rad Solutions Teleradiology Customers
10. Core Informatics Completes Successful LIMS Implementation for Progenics Pharmaceuticals
11. Alexza Completes $10 Million Equity Financing with Bio*One Capital to Initiate Commercial Manufacturing in Singapore
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... septembre 2014 Mapi, société créée à ... a été depuis 40 ans l,un des ... traditionnelles par des évaluations recentrées sur le ... impacts économiques des traitements. Logo ... A cours d,une récente conférence téléphonique avec ...
(Date:9/18/2014)... a group of rare diseases that afflict skeletal ... onset hits at the fetal stage and is ... gene encoding fibroblast growth factor receptor 3 (FGFR3) ... dysplasia, thanatophoric dysplasia (TD), a skeletal dysplasia that ... often lethal, and achondroplasia (ACH), which causes stunted ...
(Date:9/18/2014)... course of a day - car, phone, computer, ... chemical industry to turn raw materials such as ... chemicals that are the ingredients of life,s essential ... achieved outstanding progress in driving this energy intensive ... instead of fossil fuels, has won the prestigious ...
(Date:9/18/2014)... MX (PRWEB) September 18, 2014 September ... Mexico City, MX. ASEA is the manufacturer of the ... the skin care product, RENU28. , The Mexico ... Vice President Duvan Botero, and ASEA Field Leader Shawn ... holds a PhD in Atomic/Medical Physics from the University ...
Breaking Biology Technology:1974 - 2014 - Mapi fĂȘte ses 40 ans 2Researchers use iPS cells to show statin effects on diseased bone 2Researchers use iPS cells to show statin effects on diseased bone 3Using solar energy to turn raw materials into ingredients for every day life 2Announcing the ASEA Mexico Grand Opening Tour Beginning September 18th 2
... March 18 In a video interview Mike,Lawrie, CEO ... of Misys Healthcare and Allscripts to create a leader ... business. The,interview and transcript are available now on ... you warrant that you are not,located in the US ...
... - Collaboration leads to major deals in Asia,- Annual revenue to ... Sartorius Stedim Biotech expects significant demand for its products and ... ... France, GOETTINGEN, Germany and MONTREAL, Canada, March 18,/PRNewswire-FirstCall/ - Sartorius Stedim ...
... Professor Nadrian Seeman has received the American Chemical Societys ... of structural DNA nanotechnology. Created in 1902, the Nichols ... chemistry and is given by the societys New York ... Professor of Chemistry at NYU, founded and developed the ...
Cached Biology Technology:ProMetic and Sartorius Stedim Biotech collaborate on technology transfer deals in Asia 2ProMetic and Sartorius Stedim Biotech collaborate on technology transfer deals in Asia 3ProMetic and Sartorius Stedim Biotech collaborate on technology transfer deals in Asia 4
(Date:9/18/2014)... tiny strands of nucleic acid that contain instructions for ... data, our DNA is copied into RNA molecules, which ... in our cells. , Several years ago, scientists ... other known RNAs, this molecule is circular, and was ... has been known about how they are produced. Moreover, ...
(Date:9/18/2014)... across racial and ethnic groups describe losing eyesight ... day-to-day life, more so than other conditions including: ... of African-Americans, 49% of non-Hispanic whites, 43% of ... disease or ailment is the worst that could ... followed by AIDS/HIV. Hispanics and Asians ranked ...
(Date:9/18/2014)... algal forests in the eastern Mediterranean Sea pose a ... distribution continues to expand as the climate warms, a ... of researchers led by Dr Adriana Vergs of UNSW ... for Advanced Studies in Spain, is published in the ... surveyed more than 1000 kilometres of coastline in Turkey ...
Breaking Biology News(10 mins):Scientists find how mysterious 'circular RNA' is formed, claim muscular dystrophy link 2Americans rate losing eyesight as having greatest impact on their lives 2Americans rate losing eyesight as having greatest impact on their lives 3Tropical fish a threat to Mediterranean Sea ecosystems 2
... in the Pacific Ocean as the likely culprit for ... to rivers and streams along the West Coast of ... Northwest and Southwest Fisheries Science Centers are comparing data ... in 2005 that occurred when this years returning salmon ...
... TEMPE, Ariz. Taxonomy, the science responsible for species ... decades a disregard that a new International Institute ... to change. Our vision is to spark a ... and technologies, says founding director Quentin Wheeler, an entomologist ...
... Throughout the world, amateurs, experts and the media agree ... that the bodys own opioids, so called endorphins, are ... never been proved until now. Researchers at the Technische ... demonstrate the existence of an endorphin driven runners high. ...
Cached Biology News:Unfavorable ocean conditions likely cause of low 2007 salmon returns along West Coast 2Species explorers ask: What's on Your planet? 2Species explorers ask: What's on Your planet? 3The myth of runner's high revisited with brain imaging 2The myth of runner's high revisited with brain imaging 3
... provide two highly efficient methods of identifying ... preparation. By using the large-scale screen method ... do is to transfer partial colonies of ... plates into the solutions provided by the ...
HP 1 alpha Immunogen: Synthetic peptide between amino acids 1-100 of the human HP 1 alpha protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Recombinant Porcine IL-1 alpha/IL-1F1, CF...
... KLH-conjugated, synthetic peptide corresponding to ... mouse p19ARF. The epitope ... 62-75. Clone 5-C3-1. Quality ... immunoblot. Stability ...
Biology Products: